Statistics from the International Diabetic Federation show in 2010 a total of 285 million people worldwide have diabetes and it is expected to increase to 438 million by 2030.Diabetes is divided into two types 1 and 2. Most patients in this country suffer from type 2 diabetes where the pancreas does not produce sufficient quantities of insulin and indirectly it will have less impact on muscle and liver cells.Patients often have levels of blood lipids and cholesterol increases the risk of cardiovascular disease. This is the source of most of the death of patients with type 2 diabetes.For type 1 diabetes, the patient’s body does not produce insulin immediately. For every patient with diabetes should be treated and the goal is to reduce the level of blood glucose to target levels because the disease causes increased blood sugar levels.Recently, Novo Nordisk has launched Victoza, a drug developed for the treatment of type 2 diabetes. With Victoza, type 2 diabetes patients are confident in controlling blood glucose levels as well as to benefit weight loss.
Victoza is a drug that could help patients with type 2 diabetes blood glucose levels returned to normal.
It reacts with the body to control blood glucose levels by stimulating insulin production only when it becomes too high.
Victoza income is also to identify the best methods to help patients with type 2 diabetes to control blood glucose levels while reducing the risk of blood glucose levels are too low (hypoglycemia).
Before Victoza introduced to the public, a study by proving two additional benefits Victoza is systolic blood pressure reduction and recovery of beta cell function.
These advantages have been proved through phase 3 trials Liraglutide Effect and Action in Diabetes (LEAD) involving 4,000 patients with type 2 diabetes treatment in 40 countries Victoza